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SPECIAL REPORT 
Frontotemporal Dementia and Parkinsonism 
Linked to Chromosome 17: A Consensus 
Conference 
Norman L. Foster, MD,* Kirk Wilhelmsen, MD, PhD,? Anders A. F. Sima, MD, PhD,ts  
Margaret Z. Jones, MD," Constance J. D'Amato, BS,$ Sid Gilman, MD,* and Conference Participants7 
We held an international consensus conference on frontotemporal dementia, behavioral disturbances, and parkinsonism 
linked to chromosome 17 to determine whether these are homogeneous or heterogeneous disorders, to agree on termi- 
nology, and to develop strategies for further research. The group identified 13 kindreds with sufficient evidence for 
linkage, finding in common to all a critical 2 CM between markers D17S791 and D17S800. There was agreement that 
(I) despite previous descriptions that have emphasized one or another clinical or neuropathological feature, the kindreds 
share clinical and neuropathological features; (2) until more specific information about the genetic defects becomes 
available, this disorder is best termed frontotemporal dementia and parkinsonism linked to chromosome 17; and (3) 
hrther research will be enhanced by identifying the gene or genes responsible for this disorder, detecting additional cases 
within known families and, in new families, correlating mutations with phenotypes and more fully delineating the 
clinical, neuropsychological, and neuropathological characteristics of this disorder. 
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dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997;41:706-715 
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Most dementia in late life is caused by Alzheimer's dis- 
ease (AD), but neuropathological examinations some- 
times disclose other neurodegenerative disorders. In ap- 
proximately 3 to 10% of these patients, autopsy fails to 
reveal the characteristic neuropathological features of 
the common causes of dementia, including AD, stroke, 
structural lesions, Parkinson's disease, diffuse L e y  
body disease, or Picks disease [ 1,  21. The terminology 
to describe such cases varies and many names have 
been used. Nonspecific dementia is the most com- 
monly used term, but dementia lacking distinctive his- 
tology, Pick's disease without Pick bodies, and fronto- 
temporal dementia [2-61 are terms that have also been 
used. These dementias have been difficult to study be- 
cause the clinical variability makes it unclear whether 
they represent a distinct clinical syndrome. Many pa- 
tients later found to have one of these dementias were 
erroneously thought to have AD, but in some cases 
atypical features were recognized [7, 81. 
Many patients with nonspecific neuropathology or 
frontotemporal dementia have a disease that is heredi- 
tary, up to 60% in one series [ l ,  31, 9, lo].  Recently, 
dementia in 1 such family was linked to chromosome 
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17 [ 1 I ] .  Subsequently, several other families have had 
difficult-to-classif, progressive neurodegenerative dis- 
orders that have been linked to the same region of 
chromosome 17. Because these families have been con- 
sidered in isolation, their disorders have received vari- 
ous names that emphasize particular clinical or neuro- 
pathological features. This has made the disorders 
appear disparate when they in fact may have much in 
common. 
To extend our knowledge about chromosome 17- 
linked dementia, a forum was needed to bring together 
investigators who could compare the clinical and neu- 
ropathological features of the disorders in identified 
kindreds, determine whether they share common ele- 
ments, develop a consensus about these issues, and for- 
mulate strategies for further research. 
Methods 
An international consensus conference was held in Ann Ar- 
bor, Michigan, October 4 through 6, 1996. Before the meet- 
ing, the organizing committee searched the medical literature 
to identify all known kindreds with a neurodegenerative dis- 
ease linked to chromosome 17. We contacted investigators 
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who were familiar with each kindred and invited them to 
attend the meeting and to present clinical, genetic, and neu- 
ropathological data. They were also asked to identify any 
other kindreds that have been linked to chromosome 17. We 
gave the investigators a list of publications related to their 
kindreds that they checked for accuracy and completeness. 
We distributed a list of key published references to all par- 
ticipants for review before the meeting. The conference in- 
cluded clinicians, geneticists, and neuropathologists associ- 
ated with each kindred and an independent panel of senior 
commentators with expertise in dementia and neurodegen- 
erative disorders. These commentators provided perspective 
and a summary of each day's deliberations. 
At the beginning of the meeting, the organizing commit- 
tee instructed participants on procedures for achieving con- 
sensus, and the moderators used previously described meth- 
ods to encourage consensus among all participants [l2]. In a 
plenary session on the first day, the invited participants pre- 
sented the clinical, laboratory, neuropathological, and genetic 
features of each kindred showing linkage to chromosome 17 
and cases of sporadic and familial neurodegenerative disor- 
ders that clinically and neuropathologically resemble the de- 
scribed kindreds but are not known to be linked to chromo- 
some 17. O n  the second day, clinicians, neuropathologists, 
and geneticists held three discipline-specific sessions to 
present and discuss in detail the characteristics of the kin- 
dreds and to address a list of predetermined questions. In a 
final plenary session on the third day, the conclusions of the 
discipline-specific sessions were presented and discussed and 
the participants agreed on a final consensus statement. 
The conference-organizing committee provided a draft 
consensus statement in advance of the meeting to guide the 
discussions. The participants reviewed the statement and 
modified both the statement and the tables summarizing in- 
formation presented at the meeting. Members of the orga- 
nizing committee served as moderators of the discipline- 
specific sessions and recorded the results of the consensus. 
Results 
Kindreds with Frontotemporal Dementia and 
Parkinsonism Linked to Chromosome I 7  
The participants discussed 25 families they had identi- 
fied. They agreed that 8 families have disease that is 
definitely linked to the critical region of chromosome 
17 because of multipoint affected-only LOD scores 
greater than 3, and they classified 5 families as having 
disease that is probably linked because of LOD scores 
between 1 and 3 (Table I). The remaining 12 kindreds 
had similar clinical and neuropathological features but 
had only a small number of available tissue samples for 
DNA testing. In these kindreds where LOD scores 
were less than 1, there was no indication of a genetic 
mutation at another location, but linkage to chromo- 
some 17 had to be classified as uncertain. Information 
about these kindreds was tabulated, but they were oth- 
erwise not considered further in the deliberations. 
The 13 families with definitely and probably linked 
disease have been analyzed by a subset of markers that 
Table 1. Kindreds with Newodegenerative Disease Linked to Cbromosome 17 
Affected Only 
Multipoint 
Number in Pedigree LOD Score Flanking Markers Rcferences 
Definitely linked 
Irish family 1 (family Mo) 
Pallido-ponto-nigral de- 
generation (PPND) 
Familial multiple system 
7-opathy with presenile 
dementia (FMST) 
Seattle family A or BK 
Dutch family I 
Duke University family 
Hereditary dyphasic disin- 
1684 
hibition dementia 
(HDDD) family 2 
Australian family 
Probably linked 
Dutch family I1 
Dutch family I11 
Karolinska family 
Familial progressive subcor- 
tical gliosis (FPSG), fam- 
ily A 
Seattle family B 
13 of 33 in 3 generations 
35 of 303 in 8 generations 
41 of 383 in 6 generations 
18 of -60 in 3 generations 
49 of 162 in 6 generations 
16 of 41 in 5 generations 
21 of 475 in 8 generations 
26 of 172 in 5 generations 
34 of 144 in 7 generations 
30 of 169 in 5 generations 
12 of 35 in 5 generations 
17 of 67 in 5 generations 















D 17S250-D 17S943 
THRA-D 17S79 1 
No obligate recombinants 
D 17S800-D 17S790 
D 17S800-D 17S806 
No obligate recombinants 
No obligate recombinants 
No obligate recombinants 
No obligate recombinants 
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have been ordered in publicly available meiotic segre- 
gation maps (http://www.genethon.fr/genethon-en. 
html, http://www.chlc.org/) allowing direct compari- 
son of linkage data. The presence of disease in these 
families segregates with markers in the 17q21-22 re- 
gion, which includes, in all kindreds, a critical 2 cM 
between markers D17S731 and D17S800 (Fig). Link- 
age analysis used to classify kindreds was based on an 
“affected-only model” because the age-adjusted pen- 
etrance varies between families. In this model, marker 
data are used for all available family members and the 
clinical phenotypes for unaffected individuals are 
treated as unknowns. 
At least 4 fainilies have been described that have 
clinical and neuropathological features similar to those 
in families with linkage to 17q21-22, but linkage stud- 
ies have excluded this region [13]. One of these fami- 
lies has disease that is linked to chromosome 3 ,  and the 
others have not yet been determined [14]. 
In addition to evaluation for disease with linkage to 
17q21-22, many of the families have been examined 
for segregation with or mutations in other loci that are 
associated with neurodegeneration such as the genes for 
amyloid precursor protein, prion protein, presenilin 1, 
and presenilin 2. Direct sequence analysis and muta- 
tion screening have not revealed mutations that can be 
inferred to affect disease susceptibility in these genes. 
Insufficient data are available to determine whether 
other loci modulate the expression of mutations in the 
17q21-22 locus. 
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Clinical Features in Kindreds with .Disease Linked to 
Chromosome I 7  
Although some clinical features differ within kindreds 
and between kindreds, we found many features in 
I T  
common among affected individuals in the kindreds in 
which linkage to chromosome 17 has been demon- 
strated. The disease commonly begins insidiously with 
behavioral or motor manifestations, typically in the 
fifth decade and occasionally in the third, fourth, or 
sixth decade. The duration of the disease is variable, 
usually extending 10 years, but it can be as short as 3 
years and as long as 30 years. Patients may first seek 
medical attention because of cognitive impairment pro- 
gressing to dementia, parkinsonism, nonfluent aphasia, 
a change in personality, or psychosis. The principal 
clinical features consist of behavioral, cognitive, and 
motor disturbances (Table 2). These include impaired 
social conduct ranging from aggressiveness to apathy; 
hyperorality; hyperphagia; obsessive stereotyped behav- 
ior; psychosis, including delusions, paranoid ideation, 
and hallucinations; diminished speech output progress- 
ing to muteness; and a progressive frontotemporal de- 
mentia. It is noteworthy that neuropsychological exam- 
inations show disturbed executive function, whereas 
visuospatial function, orientation, and memory are rel- 
atively preserved until late in the illness. The clinical 
features are distinct from those of AD where memory 
and cognitive decline predominate. The motor ab- 
normalities consist principally of parkinsonian extra- 
pyramidal disorders with bradykinesia, rigidity, and 
postural instability, but without resting tremor. Corti- 
cospinal disturbances, muscle wasting, and fascicula- 
tions are seen in a minority of the cases. No significant 
benefit was observed with levodopa when it was tried. 
Supranuclear ophthalmoplegia and apraxia of eyelid 
opening is sometimes observed. Autonomic function is 
spared, at least early, and incontinence of both bladder 
and bowel occurs late in the course as dementia be- 
comes increasingly severe. Changes in body weight may 
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Fig. Linkage ma& for fiontotemporal demen- 
tia and parkinsonism linked to chromosome 17 
(FTDP17) families. (A) The location of the 
FTDP-17 locus is shown on an ideogram o f  a 
metaphase chromosome. The relative locations 
of gene loci and marker loci in the 17q21 re- 
gion are shown in B and C. (B) Gene loci 
have been positioned by meiotic segregation 
analysis and radiation hybrid somatic cell 
breakpoint analysis (Genome database, Welch 
Libra y, /ohits ffopkins Universiq; Wilhehsen 
K Clark L, unpublished data). (c) The loca- 
tions of genetic markers shown are based on the 
1996 Genethon map and are not drawn to 
scale. Next to each fdmily identification is a 
line that indicates the probable location of the 
disease gene f o r  that firni&. (0) Dashed lines 
indicate that the disease gene could be in a 
region that extends beyond the map shown 
in C. 
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Table 2. Common Clinical Manifestations in Kindreds with Disease DeJl'nitely Linked to Chromosome 17 
Behavioral disturbances 
Disinhibition: socially inappropriate behavior, including undue familiarity, and flamboyance in words and dress 
Apathy, remoteness and social isolation, depressed mood 
Defective judgment as in faulty financial decisions and unsafe driving habits 
Poor impulse control 
Repetitive, stereotypic, compulsive behavior, hyperreligiosity 
Psychosis with visual and auditory hallucinations, delusions and paranoia 
Alcoholism 
Verbal and physical aggressiveness 
Hyperorality with hyperphagia, including consumption of nonfood objects 
Early loss of personal awareness and neglect of personal hygiene 
Cognitive disturbances 
Early manifestations 
Relative preservation of memory, orientation, and visuospatial functions 
Speech disturbances with nonfluent aphasia 
Disorders of executive function: impaired set shifting, mental flexibility, foresight and planning 
Progressive deterioration of memory, orientation, and visuospatial functions 





Extrapyramidal disorders with parkinsonian manifestations appearing early or late in the course, characterized by brady- 
kinesia, axial and limb rigidity, postural instability, without resting tremor, unresponsive to levodopa therapy in the 
kindreds studied 
Occasionally observed 
Corticospinal disturbances with hyperreflexia, clonus, extensor plantar responses 
Axial and limb dystonia including retrocollis, myoclonus, and adventitial movements such as choreas, postural and 
Loss of voluntary eyelid opening 
Oculomotor disorders, including slowed saccades and supranuclear palsy 
Late onset of dysphagia and dysarthria 
Late onset of muscle wasting and fasciculation 
action tremors 
occur, including increases in association with hy- 
perphagia early in the course and decreases late in the 
disease, the latter often resulting from dysphagia. Epi- 
leptic seizures are rare but may occur late in the disease 
course. In contrast to those performed in patients with 
some other dementias, electroencephalographic (EEG) 
studies are often normal until late in the disease. Struc- 
tural imaging studies may show frontotemporal atro- 
phy that sometimes is asymmetric. Available functional 
imaging studies are compatible with the clinical presen- 
tation, showing frontal and anterior temporal hypoper- 
fusion or hypometabolism in a pattern different from 
that typically seen in AD, loss of presynaptic dopa- 
minergic markers, and upregulation of striatal dopam- 
inergic receptors. 
The clinical features within a single kindred are of- 
ten similar but not identical. The variability of clinical 
features within members of the same family indicates 
that environmental and other genetic factors may mod- 
ify the clinical expression of these disorders. 
Affected individuals in families with probable link- 
age are similar to those in families with definite linkage 
to chromosome 17. We were unable to identify any 
features that reliably distinguish linked families from 
families known not to be linked to chromosome 17 or 
a family with a clinically and neuropathologically sim- 
ilar disorder linked to chromosome 3 [ 141. 
Neuropathological Features in Kindreds with Disease 
Linked to Chromosome 17 
Frontotemporal atrophy is a consistent feature, and 
basal ganglia atrophy and substantia nigra depigmenta- 
tion are found in most kindreds (Table 3 ) .  Hemi- 
spheric atrophy is asymmetric in only 3 families with 
disease of probable linkage to chromosome 17. 
Microscopic examination consistently reveals neuro- 
nal loss, neuropil vacuolation of the superficial layers of 
the cerebral cortex, and gliosis in both gray and white 
matter of variable intensity (Table 4) .  In 4 kindreds 
(Irish family 1, pallido-ponto-nigral degeneration, fa- 
milial multiple system 7-opathy, and familial progres- 
sive subcortical gliosis family A), argyrophilic and/or 
7-positive neuronal inclusions without the characteris- 
tics of Pick bodies, argyrophilic and/or 7-positive glial 
inclusions, and ballooned neurons are found in all 
cases examined. One kindred (Seattle family A) shows 
this 7-positive neuronal pathology alone. Another 4 
kindreds (hereditary dysphasic disinhibition dementia 
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Table 3. Gross Bruin Neuropatho/ogy in Kindreds with Disease Linked to Chromosome 17 
No. of Brain Weight Asymmetric Distribution of Basal Ganglia Substantia Nigra 
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+ 
PPND = pallido-ponto-nigral degeneration; FMST = familial multiple system 7-opathy with presenile dementia; HDDD2 = hereditary 
dyphasic disinhibition dementia family 2; FPSC, A = familial progressive subcortical gliosis, family A; NIA = data not available; + = present; 
0 = absent. 
Table 4. Mkroscopic Neuropathology by Kindreds with Disease Linked to  Chromosome 17 
_ _ ~  
Neuronal Inclusions Glial Inclusions 
Neuronal Gray Matter (Argyrophilic (Argyrophilic Ballooned Neuropil White Matter 
Loss Gliosis andlor T + )  andlor 7+)  Cells Vacuolation Gliosis 
_. 
Definitely linked 
Irish 1 + + + + + + + 
PPND + + + + + 0 + 
FMST + + + + + + + 
Seattle A + + + 0 N/A N/A N /A 
Dutch I + + 0 0 01 + + + 
Duke 1684 + + 0 0 0 + + 
HDDD2 + + N/A NIA + + NIA 
Australian + + 0 0 + + NIA 
Probably linked 
Dutch I1 + + 0 
Dutch 111 + + 0 
Karolinska + + 0 
FPSG, A + + + 





O /  + + + 
0 + + 
0 + + 
+ + + 
0 + NIA 
I’PND = pallido-ponto-nigral degeneration; FMST = familial multiple system 7-opathy with presenile dementia; HDDDZ = hereditary 
dyphasic disinhibition dementia family 2; FPSG, A = familial progressive subcortical gliosis, family A; N/A = data not available; + = present; 
0 = absent. 
family 2, the Australian family, I h t c h  family I, and 
Dutch family 11) show ballooned neurons without as- 
sociated 7 pathology, and the remaining 4 kindreds 
lack both abnormalities. These features can be used to 
subdivide the kindreds into the following 4 groups: T 
and ballooned neuron positive; 7-positive alone; bal- 
looned neuron positive alone; and ballooned neuron 
negative. Because varying techniques have been used in 
evaluating T pathology, this classification is only tenta- 
tive. At present, it is the substantial similarities rather 
than these histological distinctions between kindreds 
that remain most remarkable. 
Semiquantitative regional histopathological examina- 
tion reveals neuronal loss and gliosis that is most severe 
in the frontal and temporal cortices, accompanied by 
neuronal loss and gliosis in the substantia nigra (Table 
5 ) .  In most cases, neurons of the hippocampal forma- 
tion are preserved. Neuronal loss with degenerative 
changes is moderate in the basal ganglia. Neuronal loss 
and gliosis of the amygdala is severe, except in 3 kin- 
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"Ballooned neurons. 
PPND = pallido-ponto-nigral degeneration; FMST = familial multiple system 7-opathy with presenile dementia: H D D D 2  = hereditary dypharic disinhibirion dementia 
family 2: FPSG, A = familial progressive subcortical gliosis, family A; 0 = absent: + = mild; + + = moderate; + + + = severe; NIA = data not available. 
dreds showing only mild changes. Motor neuron in- 
volvement was identified in 4 kindreds, consisting of 
degenerative changes of the motor cortex and/or motor 
neurons of the brainstem or spinal cord. Two patients 
in a family with definitely linked disease (Seattle family 
A) had excessive numbers of P-amyloid plaques. 
No differences are found between families with def- 
initely linked and probably linked disease, in the dis- 
tribution or severity of cortical neuronal loss and 
gliosis, basal ganglia pathology, or severity of depig- 
mentation and neuronal loss in the substantia nigra. 
Argyrophilic and .r-positive inclusions are not found in 
any cases of the families with disease of probable link- 
age. Diffuse Lewy bodies, amyloid deposition, and Pick 
bodies exceeding those expected for age are not found 
in any of the families with definitely or probably linked 
disease. Neuritic plaques excessive in number for age 
are seen only in rare cases. 
Discussion 
The highest priority in advancing knowledge of chro- 
mosome 17-linked neurodegenerative disease is to 
characterize the gene or genes responsible. Identifica- 
tion of a gene is inevitable, but the search may be pro- 
tracted. Progress in our understanding will be aided by 
collaboration to share genetic information, identify ad- 
ditional kindreds, and characterize more fully the clin- 
ical, neuropsychological, and neuropathological fea- 
tures of this disease. 
Classift'cation of Kindreds 
Clear commonalities emerged in discussions of the 
clinical and neuropathological features of the kindreds 
with disease linked to chromosome 17q21-22. The 
predominant features included a severe behavioral dis- 
order characteristic of the frontotemporal dementia 
accompanied by a parhnsonian syndrome without rest- 
ing tremor. Neuropathologically, the common features 
consisted of neuronal loss, gliosis, and spongiosis most 
severe in the frontal, temporal, and cingulate cortices, 
and neuronal loss in substantia nigra. Until the genet- 
ics of these kindreds is fully defined, it appears reason- 
able to consider them together. 
Several sporadic disorders have frontotemporal de- 
mentia and parkinsonism similar to that seen in chro- 
mosome 17-linked kindreds. The sporadic cases we 
considered were those in which no other relatives ap- 
peared to be similarly affected after a careful review of 
their medical history and considering their age at the 
time of death. The relationship of the sporadic disor- 
ders to the hereditary disorders is unknown. Although 
there are similarities, none of the names applied to 
these sporadic disorders adequately describes all of the 
linked hereditary cases. Likewise, none of the names 
used to describe a single hndred is sufficiently inclu- 
sive or descriptive to be applied to all. We therefore 
agreed to a new nomenclature. Because the dominant 
features of the hereditary disorder consist of a fronto- 
temporal dementia with parkinsonism, we adopted the 
term fiontotemporal dementia undparkinsonism linked to 
chromosome 17 (FTDP- 17). 
Need f i r  Additional Clinical Studies 
Additional clinical examinations of affected individuals 
in identified kindreds are needed to assess the extent to 
which similar features are present in all. At present, 
analysis of kindreds is hindered by difficulty in making 
direct comparisons. The frequency of specific clinical 
findings cannot now be accurately determined because 
so few cases have been described and not all pertinent 
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features have received comment. The frequency of clin- 
ical features also varies considerably during the illness, 
and longitudinal clinical observations are needed that 
note disease severity. Collaborations are encouraged for 
standardization of clinical data and performance of 
clinical studies presently available at only a few sites. A 
systematic review of available structural imaging studies 
would provide information about the utility of com- 
puted tomographic scanning and magnetic resonance 
imaging in recognizing the focal atrophic change uni- 
formly identified by gross inspection at postmortem ex- 
amination. In particular, neuropsychometric testing, 
standardized neuropsychiatric assessment, and func- 
tional brain imaging offer the possibility of distinguish- 
ing, before death, individuals with this disorder from 
those with familial AD. EEG findings appear unlikely 
to be sufficiently specific to aid in recognition of 
FTDP- 17. Neuropathological findings suggest that 
measurement of cerebrospinal fluid ‘r levels may be in- 
formative, but this has not yet been studied in these 
kindreds. There is no evidence thai- apolipoprotein E 
genotype alters the expression of these disorders. 
Need f i r  Additional Neuropathologicc;rl Studies 
The distinctive combination and disi:ribution of neuro- 
pathological findings identified in kindreds with dis- 
ease linked to chromosome 17 will assist in the iden- 
tification of suspected cases from available autopsy 
cases. The following four issues concerning the neuro- 
pathology of FTPD-17 emerged and should be evalu- 
ated further: (1) characterization of the abnormal T 
protein to detect similarities between kindreds in which 
it was found; (2) evaluation of abnormalities in density 
and distribution of cortical synapses by using immuno- 
cytochemical and morphometric techniques; (3)  deter- 
mination of the laminar distribution of cortical pathol- 
ogy within affected regions; and (4)  development of a 
protocol for consistent and appropriate handling of 
brains harvested from frontotemporal dementia cases, 
including sections, stains, and immunocytochemistry. 
To  permit comparability between cases, sections from 
the following regions should be evahated with hema- 
toxylin and eosin stain, Bielschowsky stain, and T pro- 
tein immunocytochemistry: frontal cortex; temporal 
cortex; anterior cingulate gyrus; caudate nucleus, puta- 
men, globus pallidus; amygdaloid nucleus; thalamus; 
hippocampus; midbrain with substantia nigra; pons; 
and cerebellar vermis and medulla. Collaborations are 
encouraged to assess the frequency and range of sever- 
ity of neuropathological features in specific brain re- 
gions and their relationship to clinical symptoms. 
Need for Additional Genetic Studies 
The families with FTDP-17 conceivably could be dis- 
tantly related to each other or to as yet unidentified 
families. This possibility can be assessed by searching 
for shared haplotypes that will provide clues to the 
more precise location of the susceptibility gene. A series 
of microsatellite polymorphisms that are recommended 
for haplotype comparison have been identified in the 
critical region between D17S791 and D17S800. Two 
Centre d’Etudes du Polymorphisme Humain (CEPH) 
reference subjects were agreed on for standardiza- 
tion of allele assignments (http://www.cephb.fr/ceph- 
genethon-maphtml). (Haplotypes and information 
concerning the markers and reference subjects chosen 
are posted on the World Wide Web, and the Internet 
address can be obtained from the authors. Haplotypes 
will be accepted from the scientific community and 
distributed anonymously using the web site.) 
Identzjcation of Additional Cases 
It is important to find additional families with 
FTDP-17 and to identify new members of the existing 
families. Carefully assessed subjects with sporadic dis- 
eases similar to FTDP-17 may be helpful in screening 
candidate genes for mutations. Without additional sub- 
jects, we are unlikely to define further the disease sus- 
ceptibility locus on 17q21-22. At present, the closest 
recombinants that define the region containing the dis- 
ease susceptibility locus are 2 cM apart. Additional kin- 
dreds can be identified by recognizing patients with 
typical clinical features and by postmortem examina- 
tion. Information about the clinical and neuropatho- 
logical features of this disorder should be disseminated 
widely among physicians. Physicians should encourage 
families to permit postmortem examination of patients 
with dementia and unusual behavioral and parkinso- 
nian syndromes. 
Clinicians should consider FTDP- 17 when evaluat- 
ing a broad array of patients. Suspect cases include any 
individual with the onset before age 65 years of a fa- 
milial disorder characterized by either (1) a behavioral 
disorder suggesting frontotemporal pathology or a de- 
menting disorder, especially if supported by neuropsy- 
chological studies showing difficulty with executive 
function or with functional imaging studies showing 
frontotemporal hypometabolism/perfusion; and/or (2) 
parkinsonism, especially if resting tremor is absent and 
the symptoms are nonresponsive to levodopa. Diagnos- 
tic labels applied to hereditary disorders not linked to 
genetic markers may be misleading. For example, the 
evidence that Pick‘s disease is sometimes hereditary is 
largely based on a Dutch kindred without Pick bodies 
reviewed at this conference and found to have features 
and linkage typical of FTDP- 17 [ 151. Familial progres- 
sive supranuclear palsy shares many clinical and neuro- 
pathological features with FTDP- 17 and such kindreds 
might be related to those discussed here [16]. 
Families with 2 or more affected individuals (the 
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proband and 1 or more first- or second-degree rela- 
tives) can provide information that will assist in fur- 
thering the localization of the disease gene. The family 
history should be explored carefully in any patient with 
a clinical or neuropathological profile similar to that 
described for FTDP- 17, by questioning the affected in- 
dividual, those who accompany the patient to the clin- 
ical examination, and several first- and second-degree 
relatives they identify. Consultation with a geneticist or 
genetic counselor can be helpful in thoroughly explor- 
ing the family history. Affected relatives may have de- 
mentia, parkinsonism, amyotrophy, schizophrenia, or 
schizoaffective disorder and may have a variety of di- 
agnoses that do not appear similar to the proband. 
Careful review of all available evidence may be neces- 
sary to ascertain whether relatives are affected. Families 
with as few as 4 or 5 affected individuals can be suffi- 
cient to determine probable linkage to or exclusion 
from chromosome 17q21-22 (or other known linkages 
such as chromosome 3) .  Geneticists attending the con- 
sensus conference are willing to assist or refer clinicians 
to investigators interested in ascertaining families and 
collecting specimens (addresses and telephone numbers 
are included in the supplemental materials). 
Clinicians caring for affected subjects should be cau- 
tious when interpreting genetic research data in discus- 
sions with these subjects and their families. Until the 
complete implications of inheriting specific mutations 
are known, only limited genetic counseling can be pro- 
vided. 
Heterogeneity in FTDP-17 
Although kindreds showed many clinical and neuro- 
pathological features in common, noteworthy differ- 
ences emerged. Asymmetric cerebral atrophy was found 
in 2 lundreds with prominent aphasia, although this 
and other speech/language disorders were prominent in 
many families. Further study of known affected indi- 
viduals and identification of additional families will 
provide a more complete understanding of the clinical 
and neuropathological heterogeneity in FTDP- 17. The 
available genetics data suggest that mutations of one or 
possibly a few genes on chromosome 17q21-22 ac- 
count for FTDP-17. The following two genetic mech- 
anisms could explain the heterogeneity in FTDP-17 
kindreds: (I) allelic mutations in the same genes (allelic 
heterogeneity), and (2) mutations in different genes lo- 
cated on chromosome 17q2 1-22 (locus heterogeneity). 
Many of the affected families are large and geographi- 
cally dispersed, and thus are likely to be influenced by 
heterogeneity of genetic background and diverse en- 
vironmental exposures. Hence, it is unlikely that ge- 
netic background or environmental factors contribute 
importantly to the phenotypic differences between 
families. This notion is reinforced because the high 
penetrance of the clinical and neuropathological phe- 
notypes appear to cosegregate. We make these infer- 
ences cautiously because recent work with other disor- 
ders such as Machado-Joseph disease suggests that 
substantial clinical heterogeneity can occur within fam- 
ilies with the same mutations [17]. 
Prevalence of FTDP-17 
Inadequate information exists to determine the preva- 
lence of FTDP-17; however, the number of identified 
kindreds is increasing rapidly as this condition is be- 
coming more widely known. The number of families 
identified has doubled since planning for this confer- 
ence began in October 1995. Identification of one or 
more genetic mutations will permit testing of individ- 
uals, which will help to determine the prevalence of 
this disorder. All currently identified affected individu- 
als are of Northern European descent. Additional ef- 
forts should be made to identi@ hereditary frontotem- 
poral dementia and parkinsonism in other ethnic 
groups and to determine whether there is a true geo- 
graphic or ethnic risk. Epidemiological studies that in- 
clude individuals in the fifth and sixth decades of life 
should include questions sensitive to identifying behav- 
ioral changes suggesting frontotemporal degeneration. 
Clues to the Pathogenesis of  FTDP-17 
Both T accumulation and ballooned neurons are com- 
mon to several sporadic dementing disorders. Accumu- 
lation of T protein may be important in the pathogen- 
esis, because this protein is transcribed by the region of 
chromosome 17 thought to harbor the mutations re- 
sponsible for this disease. Ballooned cells are common 
in various neurodegenerative diseases and are character- 
istic of corticobasal ganglionic degeneration [I 81. 
One of the kindreds possibly linked to chromosome 
17 demonstrated prion protein (PrP) immunoreactivity 
in tissues and intermediate proteinase K-resistant PrP 
[ 191. During the consensus conference, no evidence 
was presented suggesting an association between PrP 
and FTDP-17. No mutation of the PrP gene has been 
identified, and linkage to the PrP site on chromosome 
20 was excluded in this and other FTDP-17 kindreds. 
At present, the role played by PrP in this disease is 
under investigation (Gambetti P, personal communica- 
tion). 
Note: Readers can obtain 31 pages of additional data pre- 
sented at the conference from the National Auxiliary Publi- 
cations Service, PO Box 3513, Grand Central Station, New 
York, NY 10163-3513. The information includes a list of all 
publications on chromosome 17-linked kindreds and related 
articles identified for the conference (including abstracts, dis- 
sertations, and submitted manuscripts), additional summary 
tables of kindreds with similar features but undetermined 
linkage, clinical characteristics of linked kindreds, laboratory 
studies that have been completed in linked kindreds, recom- 
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mended neuropathological sections and  stains for diagnosis 
of FTDP- 17, and comparison with other neurodegenerative 
disorders. Request document no. 0539 I .  Remit with your 
order (not under separate cover), in US funds only, $11.05 
for photocopies or $5.00 for a microfiche. For addreses out- 
side the United States and Canada, an additional $5.50 for 
photocopies and $1.75 for microfiche is charged for postage 
and shipping. 
Conference Participants 
N. L. Foster, MD, K. Wilhelmsen, MD., PhD,  and A. A. F. 
Sima, M D ,  PhD,  served as moderators for the clinical, ge- 
netics, and neuropathology discipline-specific sessions. They, 
with M. Z. Jones, M D ,  C. J .  D’Amato, BS, and S. Gilman, 
M D ,  served as the organizing and writing committee for this 
conference. Others attending the conference contributed ex- 
tensively to the development of this report by making pre- 
pared remarks, contributing published and  unpublished data, 
participating in group discussions, and developing and re- 
viewing this statement. Those contributing to discussions 
and joining in this consensus are listed below. Those con- 
tributing data are indicated by an asterisk (*). Geneticists 
participating in the conference can assist or refer clinicians 
and are indicated by a dagger (t). Cumbridge University: 
M. G. Spillantini, l’hD*t; Columbia University: T. Lynch, 
MRCPI,’ and R. P. Mayeux, M D ;  Duke University: P. C.  
Gaskell, Jr, PH-C,* C. M. Hulette, MID,* M. A. Pericak- 
Vance, PhD,*t  and K. A. Welsh-Bohmer, PhD”; Einstein 
College of Medicine: D. W. Dickson, MI>; Erusmus Univer- 
.rity, Rotterdam, The Netherlands: P. Heutink, MD,*t J. Kros, 
MD,*  and J. C. van Swieten, MD*; Free University, Amstev- 
dam, The Netherlands: F. Arwert, PhD*t ;  Indiana University: 
M .  3. Ghetti, MD,* and J. Murrell, PhD*t; Karolinska Zn- 
stitute: L. Lannfelt, MD, PhD*; Mayo Clinic, jacksonville: M. 
Hutton, PhD*t; Michigan State Universigi: M .  Jones, M D ;  
National Institutes o f  Health: C. H. Phelps, PhD (NIA), D .  S. 
Snyder, PhD (NIA), and E. Oliver, PhD (NINDS); Oregon 
Health Sciences University: M. J. Ball, MI); University of Cid- 
+rnia, Los Angeles: J. L. Cummings, MI ) ,  and  B. L. Miller, 
MD*; University of California, San Diego: R. Katzman, M D ;  
University of California, San Francisco: K. Wilhelmsen, M D ,  
PhD’t; Uniwrsity of Iowa: L. Reed, MD,* and R. L. 
Schelper, MD, PhD’; University o f  Ken,tucky: D .  J .  Lanska, 
M D ,  MS’; University Hospital, Lund, Sweden: A. Brun, 
MD*; University of Michigan: C.  J. D’Amato, BS, J. K. Fink, 
MD,t N. L. Foster, MD,*  S. Gilman, MD, and  D .  E. Kuhl; 
University of Minnesota: D. S .  Knopman, MD*; University of 
Nebraska: Z. Wszolek, MD*; University o f  Southern Ca1;f.r- 
nia: C. A. Miller; University of Washington: T .  D. Bird, 
MD*t ;  Wushington University: C. Lendon, PhD’t; Wayne 
State University: C. Elechi, MBBS, and A. A. F. Sima, M D ,  
I’hD.* 
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